A Study of Gastric Delay in Migraine Patients (3207-003)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Migraine Disorders

Treatments: Drug: MK3207; Drug: Comparator: Placebo (unspecified)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00548353

3207-003

2007_599

MK3207-003

Details and patient eligibility

About

A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.

Enrollment: 22 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Non-smoking male or female between 18 to 45 years of age
• Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe

Exclusion criteria

• Patient has any other medical conditions other than migraine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

22 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

MK3207 Orally administered to patients with water. During each period (with and without acute migraine).

Treatment:

Drug: MK3207

2

Placebo Comparator group

Description:

MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).

Treatment:

Drug: Comparator: Placebo (unspecified)